Month: June 2026

Categories : Mental HealthTags :

‘We Cannot Ban Our Way out of a Youth Mental Health Crisis’

On By ModernMedia

Social media bans for teenagers lack evidence and pose risks, scientists say

Photo by Vlad Patana on Unsplash

Bans on teenagers’ social media use are gathering pace worldwide. Their proponents claim that social media bans will improve young people’s mental health, but what evidence supports these claims? In their new Frontiers in Developmental Psychology article, Dr Monika Neff Lind and her co-authors argue that there is no solid scientific evidence behind these bans, and reason to believe they could backfire. In this guest editorial, Neff Lind explains why she and her colleagues doubt that social media bans will work, and how bans should be evaluated to determine whether they have any positive effects.

By Monika Neff Lind, PhD

In December 2025, Australia banned young people under 16 from having social media accounts. France, Greece, Spain, Denmark, Malaysia, Norway, India, Egypt, Canada, Türkiye, and the United Kingdom are hot on their heels. French president Emmanuel Macron said, “Banning social media for those under 15: this is what scientists recommend.” American senator Brian Schatz, author of the Kids Off Social Media Act, said, “Studies have revealed that when children and teens reduce or eliminate exposure to social media for longer than a month, their mental health benefits.” Proponents of youth social media bans claim that we have strong scientific evidence showing that bans will improve teenagers’ wellbeing.

As a clinical psychologist and parent, I would be thrilled if this were true, but it is not. We do not know how social media bans will affect youth because we have never studied that question. Let me explain.

Searching for evidence

When we want to test claims like ‘banning social media improves youth wellbeing’, scientific experiments are one of our most powerful tools to figure out what is causing something to happen. In experiments testing the effects of social media restriction on wellbeing, we randomly assign people to at least two groups: one quits using social media for a period of time and the other is the control or comparison group, which continues to use social media as usual. Given the strength of ban proponents’ claims, my co-authors and I were curious to know how strong the experimental evidence supporting their position was. In our new study, we collected and reviewed all of the experiments that have tested whether social media restriction improves wellbeing, and we were shocked by what we found.

Not a single social media restriction experiment has included people under the age of 16. We do not know how social media bans will affect the young people being targeted by them because we have never tested this with them!

To be fair, sometimes strong evidence in adults warrants making the leap to apply the same conclusions to teenagers. But even that leap is not justified here. The experiments with adults show weak, null, and mixed effects, with 40% of experimental studies showing harmful effects (eg, decreased life satisfaction and increased loneliness) or no effects of social media restriction. So even when adults are told repeatedly that social media is bad for their mental health and that giving it up will help, we find, on average, few to no benefits.

Read and download the original article

Unintended consequences?

There is also good reason to believe that bans may backfire. First, enforcing a youth social media ban raises major ethical concerns. Enforcement efforts invade people’s privacy and are likely to hurt marginalized people more. For example, the technology that determines age based on selfie uploads makes more mistakes with young faces and people of color. Banned youth may also miss out on important resources and communications provided via social media, as schools, clubs, and most other youth-serving organizations use social media as a main form of communication.

What happens when enforcement efforts fail? Many young people will circumvent bans by creating fraudulent ‘adult’ accounts or lurking anonymously. They will retain access to social media without any of the benefits of parental controls or content filters enabled by youth accounts. The vast majority of young people oppose youth social media bans, and teens are well known for their defiance of top-down edicts that disregard their needs. Expect more conflict between teens and caregivers, not less.

To recap, we don’t know how social media bans will affect teens, and the bans may backfire. Yet the bans are still happening! Like other policies that consume resources, political capital, and time, it is imperative for governments to evaluate these actions by funding comprehensive assessments of the bans’ impacts.

What next?

The first step in measuring the impact of these bans is to determine if the bans actually change teenagers’ social media habits. Three months in, Australian authorities reported that close to 70% of social media accounts owned by people under 16 remained active.

Second, we need a careful and well-resourced plan to measure both positive well-being and mental health problems from multiple sources, including self-report, caregiver report, and objective behavioral data, to get a full picture of whether and how altered social media use affects youth.

Third, we need creative approaches to capture the real-world impacts of the bans, since true experiments are not possible and effects may be at the community as well as the individual level. For example, we could randomly assign a subset of youth (eg within a certain region) to delayed enactment of the ban. Whatever approach is taken, governments must collaborate with diverse stakeholders – including young people – to rigorously and openly evaluate potential impacts. Rushed or improvised assessment will leave room for politicization and motivated reasoning.

Big Tech has become infamous for ‘moving fast and breaking things’. Policymakers rushing to enact these bans risk repeating Big Tech’s mistakes and compounding the problems the bans are trying to solve. We cannot ban our way out of a youth mental health crisis. Rather than take things away, we should make things better.

About the author

Dr Monika Neff Lind is a clinical psychologist, science communicator, and researcher in digital mental health based at the University of California Irvine. See more of her work here.

Source: Frontiers

Categories : OphthalmologyTags :

Proteins in Blood Could Help Predict Retinal Degeneration in Diabetics

On By ModernMedia

A model using 71 proteins associated with retinal degradation could predict risk in diabetics

Plasma proteomic signatures for early risk stratification of diabetic retinal neurodegeneration.
Credit: Wei Wang and Huangdong Li / Zhongshan Ophthalmic Center, Sun Yat-sen University (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic patients before symptoms occur, according to a study published June 2nd in the open access journal PLOS Medicine by Huangdong Li from the Guangdong Provincial Clinical Research Center for Ocular Diseases in Guangzhou, China, and colleagues.

More than half a billion people around the world are now affected by diabetes. People with the disease are at risk of different neurodegenerative conditions, including the breakdown of the retina, the part of the eye that detects light, in a condition called diabetic retinal neurodegeneration (DRN). It can cause severe visual impairment and vision loss, and scientists believe that DRN is a “window” into the diabetic degeneration of other parts of the nervous system, including cognitive impairment and dementia, as well as degradation of nerves in peripheral areas like the fingers and toes.

Unfortunately, DRN is only detected after symptoms appear, when damage is already irreversible. To better predict who might suffer from DRN and when, the researchers sampled the blood plasma from 1492 patients in the Guangzhou Diabetic Eye Study with type 2 diabetes who did not yet have DRN, and examined the eyes of 1218 of them through scans over a six-year period. They compared their results with another 502 people with diabetes in the United Kingdom BioBank.

The researchers identified 71 different plasma proteins associated with DRN. The proteins were part of cell pathways for processes like inflammation and cellular maintenance. Using machine learning, the scientists used the protein levels in plasma to develop a predictive model called Pro-DRN which was able to improve on the best-performing model by 26 percent. The scientists have already put the model online to allow doctors to assess the risk. While Pro-DRN is based on plasma protein levels and relies on associations between protein levels and DRN and not direct causes, the authors hope that it could help doctors predict and potentially prevent neurodegeneration, using a simple blood test analysed by AI.

The authors add, “Our study suggests that early retinal nerve damage in diabetes leaves measurable signals in the blood. By combining plasma proteomics, longitudinal retinal imaging, and explainable AI, Pro-DRN may help move diabetic eye care from detecting established damage toward earlier, molecularly informed risk stratification, so that closer monitoring and future neuroprotective interventions can be directed to the people most likely to benefit.”

Provided by PLOS

Categories : General InterestTags :

Good Vibes. Great Music. Real Impact. Join the One Day x SANBS Community Blood Drive

On By ModernMedia

The South African National Blood Service (SANBS) and J’Something Bring Blood Donation into the Culture

What if saving a life was part of your weekend plans?

On 6 June 2026, music, culture, community and purpose will come together at Artistry JHB as the South African National Blood Service (SANBS), musician and entrepreneur J’Something host One Day x SANBS Community Blood Drive a unique event designed to make giving blood more accessible, engaging and relevant to a new generation of South Africans.

Every day, blood donors help create more tomorrows for patients across the country. They make it possible for someone to celebrate another birthday, return home to their family, pursue their dreams, or simply get a second chance at life. Yet many South Africans who are eligible to donate have never taken that first step.

Through this purpose-driven partnership, SANBS and J’Something are bringing blood donation into spaces where people naturally connect, create and inspire one another. By blending culture, creativity and community impact, the One Day x SANBS Community BloodDrive aims to show that donating blood is not only life-saving it’s something everyone can be part of.

The result is more than a blood drive. It’s a day party with purpose, where every donation has the potential to save up to three lives.

Blood Drive Details:

Venue: Artistry JHB

Date: 6 June 2026

Time: 09:00 – 15:00

RSVP: tshilidzim@meropa.co.za or 076 306 1197

Please RSVP by Friday,05 June 2026

Secure your spot at the blood drive by completing the quick eligibility screening below.

Whether you’re donating blood or simply coming through to support the movement, expect good music, great energy and a community united for a meaningful cause.

Click here for the quick eligibility screening.

Be the lifeline. Give Blood. Give A Tomorrow.

Categories : CancerTags :

Breakthrough Drug Nearly Doubles Survival with Advanced Pancreatic Cancer

On By ModernMedia

– an Oncologist Explains how Daraxonrasib Overcame an ‘Undruggable’ Disease

Pancreatic cancer. Credit: Scientific Animations CC BY-SA 4.0

Christopher Lieu, University of Colorado Anschutz

For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis.

Pancreatic cancer is so deadly in part because there are no effective screening tests, and it rarely causes noticeable symptoms in its earliest stages. By the time a patient experiences signs, such as jaundice – a yellowing of the skin – or abdominal pain, the cancer has often already spread to other organs.

As a gastrointestinal oncologist and researcher specialising in early-phase clinical trials, I have seen the critical need for more effective therapies for patients with pancreatic cancer. For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible.

However, that narrative is rapidly changing with a new drug that can shut down the key protein that drives pancreatic cancer, nearly doubling survival rates for patients with advanced stages of the disease.

‘Undruggable’ tumours

The standard treatment for advanced pancreatic cancer has historically relied on chemotherapy, potent drugs designed to kill rapidly dividing cells. While chemotherapy can slow the progression of the disease, its effectiveness is often limited by the ability of pancreatic cancer cells to develop resistance against these drugs.

Model of the 3D structure of KRAS, resembling a rough-looking blob with a molecule tucked inside
KRAS (blue) has been difficult for drugs to target. Fvasconcellos/Wikimedia Commons

Pancreatic cancer’s success lies in its genetics. More than 90% of pancreatic tumours are driven by mutations in a gene called KRAS. This gene codes for proteins that function as switches that turn cell growth on and off. When the KRAS gene is mutated, the switch becomes permanently stuck in the “on” position, commanding cancer cells to multiply endlessly.

For decades, scientists considered KRAS to be “undruggable.” The surface of the protein is exceptionally smooth, lacking the molecular pockets that standard drugs require to bind to and turn the switch off.

Because existing drugs haven’t been able to target this protein, treatment for pancreatic cancer has primarily relied on toxic drugs that act more like blunt instruments than precise tools. Chemotherapy attempts to control the disease through widespread cell destruction, causing significant collateral damage to healthy tissues that lead to side effects.

What is daraxonrasib?

A new drug called daraxonrasib offers a critical advance in treating metastatic pancreatic cancer.

Daraxonrasib is taken daily by mouth. Instead of binding to KRAS directly, it attaches to a molecule called cyclophilin A in cells that helps fold proteins into their final 3D structures. This protein complex is then able to bind to the active KRAS protein and shut down its ability to signal cancer cells to multiply.

The company developing the drug, Revolution Medicines, presented results on May 31, 2026, from its Phase 3 clinical trial of 500 patients with metastatic pancreatic cancer who had received prior treatment. Compared to standard chemotherapy, daraxonrasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis. Overall, daraxonrasib reduced the risk of death for metastatic pancreatic cancer patients by 60%. https://www.youtube.com/embed/sIspXSWQn1w?wmode=transparent&start=0 Daraxonrasib nearly doubled survival for patients with advanced pancreatic cancer compared to chemotherapy.

The most common side effect is a prominent skin rash, which affected more than 86% of patients in the study. Patients also frequently dealt with stomatitis – painful swelling and sores inside the mouth – as well as diarrhoea, nausea and vomiting. However, patients taking daraxonrasib were far less likely to stop treatment due to severe side effects compared to chemotherapy, and they had improved quality of life with reduced pain.

Next steps for daraxonrasib

By successfully targeting the specific genetic mutation that drives the vast majority of pancreatic cancers, researchers have demonstrated that this “undruggable” disease is treatable with targeted therapy.

The immediate next step is regulatory review of the drug’s readiness for the clinic. With data now officially published, Revolution Medicines will use these findings to seek formal approval from the Food and Drug Administration and other global regulatory bodies.

Because advanced pancreatic cancer is notoriously difficult to treat, breakthrough therapies that demonstrate this kind of significant survival benefit are often granted expedited or priority review. When daroxonrasib becomes available to patients will depend on the review timeline. Should the drug obtain approval, it could be available in clinics within months.

For the broader landscape of drug development, this milestone represents a likely shift in pancreatic cancer treatment. I expect more clinical trials exploring combination therapies pairing KRAS inhibitors with other drugs to prevent tumours from developing resistance to treatment.

Should daraxonrasib succeed, it could help set the stage for more precise, personalised and effective treatments for pancreatic cancer in the years to come.

Christopher Lieu, Professor of Medical Oncology, University of Colorado Anschutz

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Categories : Metabolic Disorders NeurologyTags :

Brain Tumour Removal May Improve Blood Sugar Control in Diabetes Patients

On By ModernMedia
Photo by Anna Shvets on Pexels

A new study published in JAMA Network Open found that removing olfactory groove meningioma, a type of brain tumour located near the base of the brain, may improve blood sugar control in patients with diabetes. 

Researchers followed patients with an olfactory groove meningioma and diabetes over five years after surgery, tracking long-term changes in haemoglobin A1c (HbA1c), which is a standard measure of blood sugar control, and body weight after tumour removal surgery. 

The research team found:

  • Blood sugar control improved after tumour removal in most patients.
  • Improvements often happened soon after surgery and lasted for years.
  • Many patients also lost weight after surgery.
  • Improvements occurred even when diabetes medications stayed the same. 

“This type of brain tumour affects both frontal lobes simultaneously and is usually thought of as causing symptoms like vision problems, personality changes or loss of smell,” said Andrew Venteicher, MD, PhD, an associate professor at the University of Minnesota Medical School and neurosurgeon with M Health Fairview. “What surprised us was how much blood sugar control improved after surgery in many of these patients. The findings may help us better counsel patients before surgery and raise new questions about how the brain influences metabolism throughout the body.”

The findings suggest that some brain tumours may affect the body’s ability to regulate metabolism and blood sugar, and that removing certain brain tumours may improve blood sugar control and weight in some patients with diabetes, in addition to improving neurological symptoms. 

Future studies will explore why these metabolic improvements occur and whether similar effects are seen in patients with other types of brain tumours. Researchers also hope to better understand how brain function, behaviour and metabolism are connected and whether these findings could help guide future treatment decisions.

Source: University of Minnesota

Categories : IT in HealthcareTags :

AI Language Models Struggle with Basic Hospital Data Tasks, Study Finds

On By ModernMedia

Nine leading AI models were tested on simple administrative queries drawn from real-world emergency department records—and most failed unless paired with code-generation tools.

A new study finds that large language models (LLMs), used with straightforward prompting, perform poorly on routine number-crunching tasks that hospital administrators depend on every day to track patients and allocate resources. The findings were published this week in the open-access journal PLOS Digital Health by Eyal Klang of the Icahn School of Medicine at Mount Sinai, New York, USA, and colleagues.

Hospitals rely on structured electronic health record (EHR) data to monitor patient counts and resources and to generate administrative reports. These tasks are currently handled by data analysts using programming languages, creating delays when staff need fast answers. AI tools known as large language models, such as GPT-4o and Llama, have been proposed to simplify that process.

In the new study, researchers evaluated nine leading LLMs on two basic administrative tasks—counting patients meeting a condition and filtering records based on multiple criteria—using data drawn from 50 000 real emergency department visits at the Mount Sinai Health System.

The researchers found that straightforward prompting—asking the model a plain question like “how many patients in this table were admitted?”—produced uniformly poor results across all models. Chain-of-thought reasoning, in which the model is prompted to show step-by-step work before giving an answer, offered only modest improvements that degraded sharply as table size increased. Even GPT-4o, the top-performing model, saw accuracy drop from roughly 95% on the smallest datasets to below 60% on larger ones under chain-of-thought conditions.

A tool-based approach—where models were asked to generate code that was then executed—substantially improved accuracy for the most capable models, with GPT-4o and Qwen-2.5-72B achieving near-perfect performance. However, distilled DeepSeek models, optimised for speed and efficiency, struggled even with this approach. One model, Llama-3.1-8B, failed to produce usable output in the majority of trials and was excluded from further analysis.

“Our findings indicate that without using a tool-based strategy, current LLMs are unsuitable for standalone use even on minimally complex administrative tasks in clinical settings,” says Benjamin Glicksberg. “Structured data tasks in clinical workflows will require agentic approaches that combine LLMs with code execution to ensure accuracy and consistency.”

Provided by PLOS

Categories : NeurologyTags :

Largest Study of New Parents Dismisses ‘Baby Brain’ Myth

On By ModernMedia

The largest and most comprehensive study of memory and cognition in new parents has found no evidence for ‘baby brain’ in parents

Photography by Drew Hays on Unsplash

New mothers often complain about having ‘baby brain’, where memory and cognition become vague and unreliable. Now a Monash University study – the largest ever done comparing cognitive ability in new parents – has unequivocally found no evidence that ‘baby brain’ reflects underlying problems with cognition that result from becoming a parent.

In a study published in the journal Cortex, and led by PhD candidate Navyann Siddiqui and Dr Kelsey Perrykkad from the Cognitive Neuroimaging Lab at the Turner Institute for Brain and Mental Health, researchers examined cognitive differences in 150 mothers and 150 fathers up to two years after their baby’s birth.

The study found that – using a comprehensive battery of cognitive assessments – both mothers and fathers showed similar performance to non-parent (male and female) controls on all cognition measures, “suggesting the absence of so-called ‘baby brain’ effects,” Dr Perrykkad said.

As an explanation of the common stereotype of ‘baby brain’, the researchers found a gender bias, with male non-fathers self-reporting better subjective memory than all other groups. However, according to Mr Siddiqui, “this self-promotion bias appeared to be lost in fathers, driven by lack of sleep”.

Strikingly, there was no effect of time postpartum on any cognitive measure, with parents’ ability on cognitive tests remaining the same regardless of the baby’s age up to 2 years, when it is assumed that sleep deprivation would be reduced.

While there is evidence of subtle decrements in cognition during pregnancy, according to Dr Perrykkad, “the evidence is inconsistent about the presence of an objective measurable decline in cognitive function during the postpartum period with studies revealing a potential mismatch between the self-reported parental experience and objective measures of cognitive change,” she said.

Mr Siddiqui said that – before the study – they expected that mothers and fathers would show subjective and objective reduction in cognition compared to non-parents. “We expected that there would be little to no difference between the new mums and dads on account of their shared environment post birth and we also expected that cognition would improve in parents with increased time postpartum,” he said.

Dr Perrykkad continued, ‘So why do new parents, especially new mothers, commonly report experiences of baby brain? It is important not to dismiss what new parents are telling us. When we do find evidence for baby brain, it is more related to sleep and wellbeing than a true objective decline in cognition. This indicates it is just as important as ever to support new parents in these formative years. While it isn’t the end of the baby brain story, new parents can take solace in the fact that becoming a new parent doesn’t inherently impair their memory and cognition.”

Source: Monash University

Categories : AgeingTags :

Genetic Trade-off Between Youth and Longevity Uncovered by Researchers

On By ModernMedia
A 3-month-old African turquoise killifish, left, and a 5-month-old killifish, right, show aging much like that in humans.

Researchers have identified a gene that directly links early-life growth and reproductive success with accelerated ageing and increased cancer risk later in life, offering new insight into a longstanding theory in evolutionary biology.

Now, an international team of researchers provides experimental evidence for the theory of antagonistic pleiotropy, the idea that certain genes can provide advantages early in life while contributing to disease and decline in old age.

What’s fascinating – and slightly terrifying – is that the cancer we see in these fish isn’t a random accident. It’s the direct shadow of their youthful vitality

Prof Itamar Harel

While widely accepted in theory, scientists have struggled to identify specific genes responsible for such trade-offs in vertebrates. Using the African turquoise killifish, a short-lived species recently pioneered by Harel and colleagues for genetic ageing research, the team focused on the gene vgll3, which has been previously linked to the timing of human puberty and maturation in other species, particularly Atlantic salmon.

By modifying this gene using CRISPR technology, the researchers observed clear effects. Fish with altered vgll3 grew faster and reached sexual maturity earlier, traits that could offer a reproductive advantage in natural environments.

However, these benefits came with significant long-term costs. The same fish showed reduced lifespans and a higher incidence of age-related tumours, including melanoma-like cancers.

“We have effectively caught evolution in the act of making a trade-off. For years, we’ve asked why our bodies can’t just maintain themselves indefinitely. This gene gives us a direct answer: nature doesn’t prioritise longevity; it prioritises continuity. We are built to sprint, not to marathon,” said Prof Itamar Harel at Hebrew University.

Further analysis showed that the gene influences key biological processes, including cell division, stem cell activity, and DNA repair. Increased cellular activity may help explain both the rapid development observed in younger fish and the accumulation of damage that leads to disease in older individuals.

The researchers also developed a new immunodeficient killifish model, enabling them to transplant and study tumour cells in ways not previously possible in this system.

“What’s fascinating – and slightly terrifying – is that the cancer we see in these fish isn’t a random accident. It’s the direct shadow of their youthful vitality. The same machinery that drives a cell to build a young body is hijacking the system to build a tumour in the old one. If we can understand this mechanism, we might finally learn how to decouple healthy growth from the disease of ageing,” Dr Harel added.

Because vgll3 is conserved in humans, the findings may have broader implications for understanding human development, ageing, and age-related diseases. While previous association studies have linked the gene to puberty timing and hormone levels, functional data were missing until now.

The discovery could contribute to future efforts in cancer prevention and research aimed at extending healthy lifespan. Researchers say the next step will be to explore whether it is possible to separate the gene’s beneficial early-life effects from its harmful consequences later in life.

Source: EurekAlert!

Categories : Cardiovascular DiseaseTags :

First-in-human Trial of Cholesterol-lowering Genetic Therapy to Begin in Australia

On By ModernMedia

Australian hospitals will lead a first-in-human clinical trial of a new investigational genetic therapy that aims to lower cholesterol in people at increased risk of cardiovascular disease. The Victorian Heart Hospital, operated by Monash Health in partnership with Monash University, will be the first clinical trial site globally to begin testing the investigational therapy STX-1150, developed by Scribe Therapeutics.

The therapy is designed to reduce LDL (‘bad’) cholesterol by targeting a gene in the liver called PCSK9, a well-established regulator of cholesterol levels and cardiovascular risk. Elevated LDL cholesterol is a major cause of atherosclerotic cardiovascular disease, including heart attacks and strokes.

STX-1150 uses a next-generation CRISPR-based approach known as epigenetic silencing. Delivered as a one-time infusion, the therapy is designed to reduce cholesterol levels for an extended period without permanently altering a person’s DNA.

Principal Investigator of the study Professor Stephen Nicholls, Director of the Victorian Heart Hospital and Victorian Heart Institute, and Professor of Cardiology at Monash University, said the trial represented another major step forward in developing more durable approaches to cardiovascular prevention.

‘The best way to treat heart disease, the leading cause of death globally, is to prevent it,’ Professor Nicholls said.

‘While existing cholesterol-lowering therapies are highly effective, many people still struggle to maintain long-term treatment due to cost, access, side effects, or the burden of ongoing medication.’

‘This new investigational therapy is designed to provide sustained cholesterol reduction following a single treatment, which could significantly change how we manage cardiovascular risk in the future. This represents the new frontier of cardiovascular medicine.’

‘It is incredibly exciting that Victorians and Australians will again play a leading role in the development of next-generation genetic therapies for heart disease.’

The Phase 1 study will assess the safety, tolerability and biological effects of STX-1150 in adults with elevated LDL cholesterol who are at increased cardiovascular risk.

The trial plans to enrol up to 64 participants across sites in Australia and New Zealand, with participants monitored for one year following treatment.

The study follows regulatory clearance from Australia’s Therapeutic Goods Administration and builds on growing international interest in genetic approaches to cardiovascular disease prevention.

About the study

  • The Phase 1 trial will evaluate STX-1150 in adults with elevated LDL cholesterol and increased cardiovascular risk.
  • The study is designed as an open-label, single ascending dose trial followed by a dose expansion phase.
  • Up to 64 participants are planned to be enrolled across Australia and New Zealand.
  • The Victorian Heart Hospital will serve as the initial clinical trial site.
  • Participants will be followed for one year after treatment.

Source: Monash University

Categories : Obstetrics & GynaecologyTags :

Why PCOS Is Now Called PMOS and What It Means for Women’s Health

On By ModernMedia
Polycystic ovaries. Credit: Scientific Animations Wiki CC4.0

For decades, women diagnosed with Polycystic Ovary Syndrome (PCOS) have often been told that the condition centres on cysts forming on the ovaries. In reality, many women who meet the diagnostic criteria never develop ovarian cysts at all, which means that the name has long created confusion for both patients and clinicians alike.

In May 2026, global health experts formally introduced Polyendocrine Metabolic Ovarian Syndrome (PMOS) as the updated terminology for this condition, which reflects the growing scientific consensus that it involves multiple hormonal and metabolic systems, not only the ovaries.

The change follows more than a decade of international consultation among endocrinologists, researchers and patient groups. The goal is to align the name of the condition with what research has increasingly shown about how it works in the body.

“Up to 70% of PCOS cases remain undiagnosed due to gaps in awareness, recognition and care, leaving many women navigating years of unexplained symptoms,” says Dr Themba Hadebe, Clinical Executive at Bonitas Medical Fund. “The new terminology recognises that this is a complex endocrine and metabolic disorder that affects several systems in the body.”

A name change to pay attention to

For years, the label Polycystic Ovary Syndrome suggested that ovarian cysts were the defining feature of the condition. Yet the small follicles seen on ultrasound scans are not true cysts, and they are not present in every patient.

Doctors diagnose the condition using a combination of symptom monitoring that may include irregular ovulation, elevated androgen levels and characteristic ovarian changes on ultrasound. This broader clinical picture often sits uneasily with the name itself.

“The terminology shaped how people understood the condition,” says Hadebe. “When patients heard ‘polycystic ovaries’, many assumed the problem was limited to reproductive health. In practice, the condition affects hormones, metabolism and long-term health risk.”

Women living with the syndrome frequently experience a wider set of health concerns. Hormonal imbalances can lead to acne, excess facial or body hair and irregular ovulation. The condition can also influence mood and mental wellbeing.

“Patients often arrive in consulting rooms with a range of symptoms that appear unrelated,” says Hadebe. “When you step back and view the condition as a broader endocrine disorder, those symptoms begin to make sense.”

One of the strongest drivers of the renaming is the role of metabolism in the condition. Research shows that many women living with the syndrome experience insulin resistance, where the body’s cells respond poorly to insulin and struggle to regulate blood sugar effectively. This metabolic disruption can contribute to weight gain and increase the risk of developing Type 2 Diabetes and cardiovascular disease later in life.

The importance of early diagnosis

Despite how common the condition is, many women spend years searching for answers before receiving a diagnosis, with updated NICE guidelines for PMOS aimed at standardising diagnostic pathways expected to be released towards the end of 2026. Symptoms such as irregular periods, persistent acne, excess hair growth or unexplained weight gain are often dismissed as routine hormonal fluctuations.

Delayed diagnosis can carry long-term consequences. Without proper management, metabolic complications may develop gradually over time. “Early detection allows clinicians to manage the condition more effectively and reduce future health risks,” says Hadebe. “Women who notice persistent hormonal or menstrual changes should seek medical advice so that underlying causes can be assessed.”

Addressing stigma and misunderstanding

The name change also addresses the emotional impact many women describe when navigating the condition. Patients frequently report that their symptoms were minimised or attributed to stress, weight or lifestyle factors before they received an explanation.

Language plays a powerful role in shaping how conditions are understood. A name that reflects the complexity of the syndrome helps validate the experiences of those living with it.

“Renaming the condition does not change the biology,” says Hadebe. “However, updating the name to better reflect current scientific understanding will improve awareness, support earlier diagnosis, enhance quality of care, drive greater consistency in research, and ultimately improve the overall patient experience.”

As awareness grows, experts hope the shift to Polyendocrine Metabolic Ovarian Syndrome, or PMOS, will encourage earlier recognition of symptoms and more holistic care for women affected by the condition.